<?xml version='1.0' encoding='utf-8'?>
<document id="29255993"><sentence text="Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining." /><sentence text="Our aim was to describe prevalence, nature, and level of severity of potential statin drug-drug interactions in a university hospital" /><sentence text="" /><sentence text="In a cross-sectional study, statin drug-drug interactions were screened from medical record of 10,506 in-patients treated stored in the clinical data warehouse &quot;eHOP" /><sentence text="&quot; We screened drug-drug interactions using Theriaque and Micromedex drug databases" /><sentence text="" /><sentence text="A total of 22" /><sentence text="5% of patients were exposed to at least one statin drug-drug interaction" /><sentence text=" Given their lipophilicity and CYP3A4 metabolic pathway, atorvastatin and simvastatin presented a higher prevalence of drug-drug interactions while fluvastatin presented the lowest prevalence"><entity charOffset="57-69" id="DDI-PubMed.29255993.s9.e0" text="atorvastatin" /><entity charOffset="74-85" id="DDI-PubMed.29255993.s9.e1" text="simvastatin" /><entity charOffset="148-159" id="DDI-PubMed.29255993.s9.e2" text="fluvastatin" /><pair ddi="false" e1="DDI-PubMed.29255993.s9.e0" e2="DDI-PubMed.29255993.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29255993.s9.e0" e2="DDI-PubMed.29255993.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29255993.s9.e0" e2="DDI-PubMed.29255993.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29255993.s9.e1" e2="DDI-PubMed.29255993.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29255993.s9.e1" e2="DDI-PubMed.29255993.s9.e2" /></sentence><sentence text=" Up to 1% of the patients was exposed to a contraindicated drug-drug interaction, the most frequent drug-drug interaction involving influx-transporter (i" /><sentence text="e" /><sentence text=", OATP1B1) interactions between simvastatin or rosuvastatin with cyclosporin"><entity charOffset="32-43" id="DDI-PubMed.29255993.s12.e0" text="simvastatin" /><entity charOffset="47-59" id="DDI-PubMed.29255993.s12.e1" text="rosuvastatin" /><entity charOffset="65-76" id="DDI-PubMed.29255993.s12.e2" text="cyclosporin" /><pair ddi="false" e1="DDI-PubMed.29255993.s12.e0" e2="DDI-PubMed.29255993.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29255993.s12.e0" e2="DDI-PubMed.29255993.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29255993.s12.e0" e2="DDI-PubMed.29255993.s12.e2" /><pair ddi="false" e1="DDI-PubMed.29255993.s12.e1" e2="DDI-PubMed.29255993.s12.e1" /><pair ddi="false" e1="DDI-PubMed.29255993.s12.e1" e2="DDI-PubMed.29255993.s12.e2" /></sentence><sentence text=" The second most frequent contraindicated drug-drug interaction involved CYP3A4 interaction between atorvastatin or simvastatin with either posaconazole or erythromycin"><entity charOffset="100-112" id="DDI-PubMed.29255993.s13.e0" text="atorvastatin" /><entity charOffset="116-127" id="DDI-PubMed.29255993.s13.e1" text="simvastatin" /><entity charOffset="140-152" id="DDI-PubMed.29255993.s13.e2" text="posaconazole" /><entity charOffset="156-168" id="DDI-PubMed.29255993.s13.e3" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.29255993.s13.e0" e2="DDI-PubMed.29255993.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29255993.s13.e0" e2="DDI-PubMed.29255993.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29255993.s13.e0" e2="DDI-PubMed.29255993.s13.e2" /><pair ddi="false" e1="DDI-PubMed.29255993.s13.e0" e2="DDI-PubMed.29255993.s13.e3" /><pair ddi="false" e1="DDI-PubMed.29255993.s13.e1" e2="DDI-PubMed.29255993.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29255993.s13.e1" e2="DDI-PubMed.29255993.s13.e2" /><pair ddi="false" e1="DDI-PubMed.29255993.s13.e1" e2="DDI-PubMed.29255993.s13.e3" /><pair ddi="false" e1="DDI-PubMed.29255993.s13.e2" e2="DDI-PubMed.29255993.s13.e2" /><pair ddi="false" e1="DDI-PubMed.29255993.s13.e2" e2="DDI-PubMed.29255993.s13.e3" /></sentence><sentence text=" Furthermore, our analysis showed some discrepancies between Theriaque and Micromedex in the prevalence and the nature of drug-drug interactions" /><sentence text="" /><sentence text="Different drug-drug interaction profiles were observed between statins with a higher prevalence of CYP3A4-based interactions for lipophilic statins" /><sentence text=" Analyzing the three most frequent DDIs, the more significant DDIs (level 1: contraindication) were reported for transporter-based DDI involving OATP1B1 influx transporter" /><sentence text=" These points are of concern to improve prescriptions of statins" /><sentence text="" /></document>